Antinociceptive action of hemopressin in experimental hyperalgesia

Peptides. 2005 Mar;26(3):431-6. doi: 10.1016/j.peptides.2004.10.026.

Abstract

Endogenous hemorphins, derived from degradation of the beta-chain of hemoglobin, lower arterial blood pressure and exert an antinociceptive action in experimental models of nociception. Hemopressin, derived from the alpha-chain of hemoglobin, also decreases blood pressure, but its effects on pain have not been studied. In this work, we examined the influence of hemopressin on inflammatory pain. Hemopressin reverted the hyperalgesia induced by either carrageenin or bradykinin when injected concomitantly or 2.5 h after the phlogistic agents. Hemopressin administered systemically also reverted the hyperalgesia induced by carrageenin. Naloxone did not prevent the antinociceptive action of this peptide. These data suggest that hemopressin inhibits peripheral hyperalgesic responses by mechanisms independent of opioid receptor activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology
  • Animals
  • Blood Pressure
  • Bradykinin / pharmacology
  • Carrageenan / pharmacology
  • Disease Models, Animal
  • Endorphins
  • Hemoglobins / chemistry
  • Hemoglobins / pharmacology*
  • Hyperalgesia / chemically induced
  • Hyperalgesia / drug therapy*
  • Inflammation
  • Male
  • Naloxone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Pain
  • Pain Measurement
  • Peptide Fragments / pharmacology*
  • Peptides / chemistry
  • Peptides / therapeutic use
  • Rats
  • Rats, Wistar
  • Receptors, Opioid / chemistry
  • Time Factors

Substances

  • Analgesics
  • Endorphins
  • Hemoglobins
  • Narcotic Antagonists
  • Peptide Fragments
  • Peptides
  • Receptors, Opioid
  • hemopressin
  • Naloxone
  • Carrageenan
  • Bradykinin